Cord Blood Transplantation for Blood Cancer

This trial explores the effectiveness of cord blood transplants for treating blood cancer in children and young adults. Researchers aim to determine how well this method works as either the first or second transplant option. The trial includes two groups: one for patients with high-risk blood cancer who haven't had a transplant yet, and another for those who need a second transplant due to disease recurrence. Ideal participants have specific types of blood cancer and no suitable donor available within four weeks. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important medical advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Studies have shown that Cord Blood Transplantation (CBT) is generally well-tolerated in patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Research indicates that CBT can lead to higher overall survival rates compared to some other treatments. Specifically, one study found that patients receiving CBT had better survival outcomes and a lower chance of cancer recurrence.

However, some risks exist. For instance, a study found that while CBT reduced the chance of cancer returning, it also increased the risk of death from non-cancer-related causes. This suggests that although the cancer might not return, other risks are involved.

Cord blood transplantation is unique because it utilizes stem cells from umbilical cord blood, offering an alternative for patients who lack a suitable human leukocyte antigen (HLA)-matched donor. Unlike traditional bone marrow transplants, cord blood is more readily available and can be used even when perfect donor matches aren't found, providing a crucial option for patients with high-risk and very high-risk blood cancers. Researchers are excited about this approach because it may allow for transplants in cases where conventional donor sources aren't accessible, potentially increasing survival rates for patients with aggressive forms of blood cancer.

Research has shown that cord blood transplants can effectively treat blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In this trial, participants in Cohort 1, who have high-risk disease and are in complete remission, will receive cord blood transplants. Studies have found that cord blood transplants often lead to better chances of remaining cancer-free and lower recurrence rates compared to other donor types. For patients with high-risk AML, cord blood transplants are associated with significantly lower relapse rates and improved chances of living longer without disease progression. Participants in Cohort 2, who have very high-risk disease and may have had prior transplants, will also receive cord blood transplants. Specifically, another study found that AML and MDS patients who received cord blood transplants had relatively high long-term survival rates. Overall, cord blood transplants have demonstrated excellent results, making them a promising option for those needing a transplant.⁵⁶⁷⁸⁹